Currently Viewing:
Evidence-Based Diabetes Management September 2017

After 20 Years of Watching Diabetes Tech, Kliff Eyes Smart Insulin Pens, CGM for Patients With Type 2 Diabetes

Andrew Smith
An experienced market watcher who has diabetes predicts the key to success will come down to one factor: ease of use.
KLIFF: This isn’t just for people with T1D. Monitors have already gotten to the point that they probably make sense for people with T2D, and if they’re not there yet, then they certainly will be by the next generation, which, in addition to its other advantages, should be cheaper than the current generation.

The same data that can tell doctors whether type 1 patients do or don’t comply with their treatment protocols can tell doctors whether type 2 patients are complying with their treatment protocols. It doesn’t matter whether the medication is insulin or something else. The data will show an experienced eye when patients take medicine. It will also give doctors more data than they’ve ever had about how narrow a range of blood sugar each individual patient can maintain with any protocol, and that will give doctors more feedback and more ability to fine tune than they have ever had before.

All CGM makers want to expand to the type 2 market because it is so much bigger. Really, all companies that can conceivably make their products helpful for type 2 patients will make such patients a priority. It’s simple math.

References

  1. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies with type 2 diabetes. Diabetes Ther. 2013;4(2):175-194. doi: 10.1007/s13300-013-0034-y.

  2. Zullig LL, Gellad WF, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139-149. doi: 10.2147/PPA.S69651.

  3. FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decisions [press release]. Silver Spring, MD: FDA; December 20, 2016. fda.gov/newsevents/newsroom/pressannouncements/ucm534056.htm. Accessed July 23, 2017.

  4. Tilleskjor S. Breaking news: FDA approves the MiniMed 670G system, world’s first hybrid closed-loop system. Medtronic website. medtronicdiabetes.com/blog/introducing-the-minimed-670g-system/.Published September 29, 2016. Accessed July 23, 2017.

  5. Companion Medical receives FDA clearance for smart insulin delivery system [press release]. San Diego, CA: PR Newswire; July 27, 2016. prnewswire.com/news-releases/companion-medical-receives-fdaclearance-for-smart-insulin-delivery-system-300304933.html. Accessed July 23, 2017.

  6. Common Sensing begins study with cloud-based insulin-monitoring solution to address $5B treatment management challenge [press release]. Cambridge, MA: PR Newswire; October 18, 2016.
prnewswire.com/newsreleases/common-sensing-begins-study-with-cloud-based-insulinmonitoring-solution-to-address-5b-treatment-managementchallenge-300344709.html. Accessed July 31, 2016.

  7. Bigfoot Biomedical acquires Timesulin [press release]. Milpitas, CA: Bigfoot Biomedical; June 8, 2017. bigfootbiomedical.com/bigfoot-acquirestimesulin/. Accessed June 23, 2017.
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!